MedTrace Logo

Determining the Minimal Amount of Exercise to Improve Glycaemic Control

NCT04129268 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2023-05-22

No results posted yet for this study

Summary

In 2015, there were 415 million adults worldwide with type II diabetes and by 2040, typeII diabetes will affect one in ten adults worldwide. Type II diabetes reduces quality of life and total lifespan, and two of the best countermeasures to type II diabetes are not drugs, but diet and exercise. Several studies have investigated the effects of exercise modality (aerobic, resistance, or concurrent) on glycaemic control and the mechanisms of these benefits. However, the minimal 'dose' of exercise required to increase insulin sensitivity and improve glycaemic control has never been established. Secondly, there is a progressive loss of muscle structure and function with age, which is known as sarcopenia. This study will also investigate whether the minimal amount of exercise is influenced by biological age and muscle mass by comparing physiological and biochemical responses in BMI-matched young and old volunteers. This study will therefore provide pilot data on the effect of age on exercise-mediated glycaemic control.

Conditions

Interventions

OTHER

Cycle ergometry exercise at 60% VO2max

Participants visit the lab on four occasions to complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; (iv) or 700kcal exercise (randomised).

Sponsors & Collaborators

  • Lancaster University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-10-01
Primary Completion
2022-09-26
Completion
2022-09-29

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04129268 on ClinicalTrials.gov